227 related articles for article (PubMed ID: 24727254)
1. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.
Udell JA; Morrow DA; Jarolim P; Sloan S; Hoffman EB; O'Donnell TF; Vora AN; Omland T; Solomon SD; Pfeffer MA; Braunwald E; Sabatine MS
J Am Coll Cardiol; 2014 Jun; 63(22):2421-8. PubMed ID: 24727254
[TBL] [Abstract][Full Text] [Related]
2. Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trial.
Bergmark BA; Udell JA; Morrow DA; Jarolim P; Kuder JF; Solomon SD; Pfeffer MA; Braunwald E; Sabatine MS
Eur J Heart Fail; 2019 Apr; 21(4):462-470. PubMed ID: 30773798
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease.
Sabatine MS; Morrow DA; de Lemos JA; Omland T; Sloan S; Jarolim P; Solomon SD; Pfeffer MA; Braunwald E
Circulation; 2012 Jan; 125(2):233-40. PubMed ID: 22179538
[TBL] [Abstract][Full Text] [Related]
4. Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure.
Wohlfahrt P; Melenovsky V; Kotrc M; Benes J; Jabor A; Franekova J; Lemaire S; Kautzner J; Jarolim P
JACC Heart Fail; 2015 Oct; 3(10):829-39. PubMed ID: 26450001
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
Braunwald E; Domanski MJ; Fowler SE; Geller NL; Gersh BJ; Hsia J; Pfeffer MA; Rice MM; Rosenberg YD; Rouleau JL;
N Engl J Med; 2004 Nov; 351(20):2058-68. PubMed ID: 15531767
[TBL] [Abstract][Full Text] [Related]
6. The effect of angiotensin-converting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial.
Alzahrani T; Tiu J; Panjrath G; Solomon A
Ther Adv Cardiovasc Dis; 2018 Dec; 12(12):351-359. PubMed ID: 30442080
[TBL] [Abstract][Full Text] [Related]
7. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.
Solomon SD; Rice MM; A Jablonski K; Jose P; Domanski M; Sabatine M; Gersh BJ; Rouleau J; Pfeffer MA; Braunwald E;
Circulation; 2006 Jul; 114(1):26-31. PubMed ID: 16801465
[TBL] [Abstract][Full Text] [Related]
8. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
Bergmark BA; Udell JA; Morrow DA; Cannon CP; Steen DL; Jarolim P; Budaj A; Hamm C; Guo J; Im K; Kuder JF; Braunwald E; Sabatine MS; O'Donoghue ML
JAMA Cardiol; 2018 Jun; 3(6):473-480. PubMed ID: 29710336
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
[TBL] [Abstract][Full Text] [Related]
10. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
Køber L; Torp-Pedersen C; Carlsen JE; Bagger H; Eliasen P; Lyngborg K; Videbaek J; Cole DS; Auclert L; Pauly NC
N Engl J Med; 1995 Dec; 333(25):1670-6. PubMed ID: 7477219
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.
Omland T; Sabatine MS; Jablonski KA; Rice MM; Hsia J; Wergeland R; Landaas S; Rouleau JL; Domanski MJ; Hall C; Pfeffer MA; Braunwald E;
J Am Coll Cardiol; 2007 Jul; 50(3):205-14. PubMed ID: 17631211
[TBL] [Abstract][Full Text] [Related]
12. New considerations relating to class effect with angiotensin-converting enzyme inhibitors--the PEACE study.
Sica DA
J Clin Hypertens (Greenwich); 2005 Mar; 7(3):188-93. PubMed ID: 15785163
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast Growth Factor-23, Heart Failure Risk, and Renin-Angiotensin-Aldosterone-System Blockade in Hypertension: The MESA Study.
Akhabue E; Vu TT; Vaidya A; Michos ED; de Boer IH; Kestenbaum B; Allison M; Szklo M; Ouyang P; Yancy CW; Wolf M; Isakova T; Carnethon MR
Am J Hypertens; 2019 Jan; 32(1):18-25. PubMed ID: 30256890
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study.
Torp-Pedersen C; Køber L; Carlsen J
Am Heart J; 1996 Jul; 132(1 Pt 2 Su):235-43. PubMed ID: 8677862
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis.
Kestenbaum B; Sachs MC; Hoofnagle AN; Siscovick DS; Ix JH; Robinson-Cohen C; Lima JA; Polak JF; Blondon M; Ruzinski J; Rock D; de Boer IH
Circ Heart Fail; 2014 May; 7(3):409-17. PubMed ID: 24668259
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor-23 and cardiovascular events in CKD.
Scialla JJ; Xie H; Rahman M; Anderson AH; Isakova T; Ojo A; Zhang X; Nessel L; Hamano T; Grunwald JE; Raj DS; Yang W; He J; Lash JP; Go AS; Kusek JW; Feldman H; Wolf M;
J Am Soc Nephrol; 2014 Feb; 25(2):349-60. PubMed ID: 24158986
[TBL] [Abstract][Full Text] [Related]
19. Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.
O'Donoghue ML; Mallat Z; Morrow DA; Benessiano J; Sloan S; Omland T; Solomon SD; Braunwald E; Tedgui A; Sabatine MS
Clin Chem; 2011 Sep; 57(9):1311-7. PubMed ID: 21784767
[TBL] [Abstract][Full Text] [Related]
20. Predictors of heart failure in patients with stable coronary artery disease: a PEACE study.
Lewis EF; Solomon SD; Jablonski KA; Rice MM; Clemenza F; Hsia J; Maggioni AP; Zabalgoitia M; Huynh T; Cuddy TE; Gersh BJ; Rouleau J; Braunwald E; Pfeffer MA;
Circ Heart Fail; 2009 May; 2(3):209-16. PubMed ID: 19808342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
